CHAPEL HILL, N.C.--(BUSINESS WIRE)--Sept. 13, 2005--POZEN Inc.
(NASDAQ: POZN) announced today that John R. Plachetka, Pharm.D., the
company's chairman, president and chief executive officer, will be
speaking to investors at the UBS Global Life Sciences Conference on
Tuesday, September 27, 2005 at 10:30 a.m. Eastern Time in New York
City. Dr. Plachetka's presentation will be webcast and archived on
POZEN's home page at www.pozen.com.
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. Since its
inception, POZEN has focused its efforts primarily on the development
of pharmaceutical products for the treatment of migraine. POZEN is
also exploring the development of product candidates in other
pain-related therapeutic areas. POZEN has development and commercial
alliances with GlaxoSmithKline, Valeant Pharmaceuticals North America,
a subsidiary of Valeant Pharmaceuticals International (formerly Xcel
Pharmaceuticals, Inc.), and Nycomed Danmark ApS. The company's common
stock is traded on The Nasdaq Stock Market under the symbol "POZN".
For detailed company information, including copies of this and other
press releases, see POZEN's website: www.pozen.com.
Bill Hodges, Chief Financial Officer
Fran Barsky, Director, Investor Relations
SOURCE: POZEN Inc.